Medical management of Crohn's disease

Paul A. Feldman, Daniel Wolfson, Jamie S Barkin

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The clinical course of Crohn's disease (CD) is characterized by unpredictable phases of disease activity and quiescence. The majority of CD patients experience mild to moderate disease or are in clinical remission over significant periods during the course of their disease. These patients can be treated conservatively with 5-aminosalicylates or budesonide depending on the disease location. Those patients with more severe forms of the disease who require corticosteroids should be treated more aggressively with early introduction of immunomodulator and/or biologic therapy, which may help to prevent the complications associated with CD. It has been suggested that therapies directed at mucosal healing may favorably modify the natural history of CD. As newer, more effective medications become available and new therapeutic approaches are introduced (top-down therapy), mucosal healing, and not solely clinical remission, may well become the preferred treatment objective.

Original languageEnglish
Pages (from-to)269-281
Number of pages13
JournalClinics in Colon and Rectal Surgery
Volume20
Issue number4
DOIs
StatePublished - Oct 1 2007

Fingerprint

Crohn Disease
Mesalamine
Budesonide
Biological Therapy
Immunologic Factors
Therapeutics
Adrenal Cortex Hormones

Keywords

  • Crohn's disease
  • Medical management

ASJC Scopus subject areas

  • Gastroenterology
  • Surgery

Cite this

Medical management of Crohn's disease. / Feldman, Paul A.; Wolfson, Daniel; Barkin, Jamie S.

In: Clinics in Colon and Rectal Surgery, Vol. 20, No. 4, 01.10.2007, p. 269-281.

Research output: Contribution to journalArticle

Feldman, Paul A. ; Wolfson, Daniel ; Barkin, Jamie S. / Medical management of Crohn's disease. In: Clinics in Colon and Rectal Surgery. 2007 ; Vol. 20, No. 4. pp. 269-281.
@article{9daf2848c4a54c3bbc0ab3b9a23ccbe3,
title = "Medical management of Crohn's disease",
abstract = "The clinical course of Crohn's disease (CD) is characterized by unpredictable phases of disease activity and quiescence. The majority of CD patients experience mild to moderate disease or are in clinical remission over significant periods during the course of their disease. These patients can be treated conservatively with 5-aminosalicylates or budesonide depending on the disease location. Those patients with more severe forms of the disease who require corticosteroids should be treated more aggressively with early introduction of immunomodulator and/or biologic therapy, which may help to prevent the complications associated with CD. It has been suggested that therapies directed at mucosal healing may favorably modify the natural history of CD. As newer, more effective medications become available and new therapeutic approaches are introduced (top-down therapy), mucosal healing, and not solely clinical remission, may well become the preferred treatment objective.",
keywords = "Crohn's disease, Medical management",
author = "Feldman, {Paul A.} and Daniel Wolfson and Barkin, {Jamie S}",
year = "2007",
month = "10",
day = "1",
doi = "10.1055/s-2007-991026",
language = "English",
volume = "20",
pages = "269--281",
journal = "Clinics in Colon and Rectal Surgery",
issn = "1531-0043",
publisher = "Thieme Medical Publishers",
number = "4",

}

TY - JOUR

T1 - Medical management of Crohn's disease

AU - Feldman, Paul A.

AU - Wolfson, Daniel

AU - Barkin, Jamie S

PY - 2007/10/1

Y1 - 2007/10/1

N2 - The clinical course of Crohn's disease (CD) is characterized by unpredictable phases of disease activity and quiescence. The majority of CD patients experience mild to moderate disease or are in clinical remission over significant periods during the course of their disease. These patients can be treated conservatively with 5-aminosalicylates or budesonide depending on the disease location. Those patients with more severe forms of the disease who require corticosteroids should be treated more aggressively with early introduction of immunomodulator and/or biologic therapy, which may help to prevent the complications associated with CD. It has been suggested that therapies directed at mucosal healing may favorably modify the natural history of CD. As newer, more effective medications become available and new therapeutic approaches are introduced (top-down therapy), mucosal healing, and not solely clinical remission, may well become the preferred treatment objective.

AB - The clinical course of Crohn's disease (CD) is characterized by unpredictable phases of disease activity and quiescence. The majority of CD patients experience mild to moderate disease or are in clinical remission over significant periods during the course of their disease. These patients can be treated conservatively with 5-aminosalicylates or budesonide depending on the disease location. Those patients with more severe forms of the disease who require corticosteroids should be treated more aggressively with early introduction of immunomodulator and/or biologic therapy, which may help to prevent the complications associated with CD. It has been suggested that therapies directed at mucosal healing may favorably modify the natural history of CD. As newer, more effective medications become available and new therapeutic approaches are introduced (top-down therapy), mucosal healing, and not solely clinical remission, may well become the preferred treatment objective.

KW - Crohn's disease

KW - Medical management

UR - http://www.scopus.com/inward/record.url?scp=35549006718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35549006718&partnerID=8YFLogxK

U2 - 10.1055/s-2007-991026

DO - 10.1055/s-2007-991026

M3 - Article

C2 - 20011423

AN - SCOPUS:35549006718

VL - 20

SP - 269

EP - 281

JO - Clinics in Colon and Rectal Surgery

JF - Clinics in Colon and Rectal Surgery

SN - 1531-0043

IS - 4

ER -